title: Growth hormone treatment in children: review of safety and efficacy.
abstract: Since the advent of growth hormone (GH), the pediatric applications of GH therapy have expanded. Children with a wide variety of growth disorders have received GH treatment. The therapeutic effects and safety profile of GH in a number of pediatric conditions are reviewed, including GH deficiency (GHD), Turner syndrome, chronic renal failure, children born small for gestational age, Prader-Willi syndrome, juvenile chronic arthritis, and cystic fibrosis. GH therapy has been clearly shown to improve height velocity during childhood in a variety of pediatric conditions in which growth is compromised. There is now data that confirms GH treatment also improves final height in a number of diagnostic subgroups. Early initiation and individualization of GH treatment has the potential to normalize childhood growth in children with idiopathic GHD and enable them to achieve their genetic target height in a cost-effective manner. In children in whom GHD is not the main factor compromising growth, supra-physiological doses of GH have been shown to increase height velocity during childhood and final height. The development of predictive models for these conditions may allow further improvements in height outcome while maintaining an acceptable safety profile. Survivors of childhood malignancy, particularly those who have had craniospinal irradiation, represent a particularly challenging group. They appear to be less responsive to GH than children with idiopathic GHD and have a tendency to enter puberty at an earlier age. Both of these factors have a negative impact on their final height. Strategies that combine GH treatment with suppression of puberty using a gonadotropin releasing hormone analog may result in improved height outcomes. When children with GHD are treated with standard doses of GH there is a strong safety record. Adverse events during GH therapy are uncommon and often not drug related. Continued surveillance into adult life is crucial however, particularly in children receiving supra-physiological doses of GH or whose underlying condition increases their risk of adverse effects.
authors.affiliation: Department of Paediatrics, University of Auckland, Auckland, New Zealand.
authors.forename: Mark
authors.initials: M
authors.lastname: Harris
authors.forename: Paul L
authors.initials: PL
authors.lastname: Hofman
authors.forename: Wayne S
authors.initials: WS
authors.lastname: Cutfield
mesh_terms: D002648:Child; D006130:Growth Disorders / Q000188:drug therapy / Q000628:therapy*; D019382:Human Growth Hormone / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone